Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
4,726 total articles
Brian Titus, vice president, controller and principal accounting officer at Corteva, sold 8,311 shares of the company on February 20, 2026, for proceeds of $636,199. The transactions, disclosed on a Form 4 filing with the SEC, occurred as Corteva shares traded close to a 52-week high. Titus also exercised stock options and had a portion of vested r…
North Run Strategic Opportunities Fund I, LP and affiliated entities disposed of 733,354 shares of LightPath Technologies Inc. Class A common stock between Feb. 20 and Feb. 24, 2026, generating roughly $9.1 million. The transactions followed a conversion of 1,260,000 Series G preferred shares into common stock. LightPath reported fiscal Q2 2026 rev…
Pentwater Capital Management disclosed a $40.06 million acquisition of Avis Budget Group (CAR) shares on February 20, 2026, and completed a sequence of options trades later that week. The firm now holds 4,072,300 shares after buying 425,000 shares at a weighted average price of $94.259. The transactions coincide with Avis Budget's Q4 2025 results, …
Barbara G. McClung, Chief Legal Officer of Caribou Biosciences (NASDAQ: CRBU), sold 6,938 shares on February 24, 2026, at $1.96 per share to satisfy tax obligations tied to vested restricted stock units. The stock has since traded up to $2.14, marking a 32% increase over the past week and a 73% advance year-over-year. McClung was also granted 45,00…
Fold Holdings, Inc. (NASDAQ: FLD) Chief Financial Officer Wolfe Repass sold 16,585 common shares on February 20 and 23, 2026 to cover tax-withholding tied to the vesting and settlement of restricted stock units. The transactions, executed at prices between $1.49 and $1.546 and totaling about $25,406, coincided with Repass converting 39,133 RSUs int…
Natural Alternatives International Inc. CEO Mark A. Ledoux acquired 2,000 shares of company stock between February 20 and February 24, 2026, spending roughly $5,398. The buys occurred as the share price hovered near a 52-week low and followed an SEC filing that the company obtained a Waiver and Release Agreement from Wells Fargo related to covenant…
Oregon Community Foundation, which holds roughly ten percent of Jewett-Cameron Trading Co LTD, executed two stock sales totaling 7,414 shares on February 23 and 24, 2026, raising $13,363. The transactions reduced the foundation's stake to 778,545 shares. The trades occurred against a backdrop of a difficult fourth quarter for Jewett-Cameron, which …
Caribou Biosciences NASDAQ:CRBU Chief Technology Officer Timothy P. Kelly reported a February 24, 2026 sale of 3,147 shares at $1.96 per share, yielding $6,168. A Form 4 shows Kelly also acquired 45,000 common shares on February 20, 2026, valued at $0, and obtained options to purchase 202,500 shares at a $1.80 exercise price expiring February 19, 2…
Caribou Biosciences NASDAQ:CRBU Chief Medical Officer Tina M. Albertson sold 1,066 shares on February 24, 2026, for $1.96 per share, totaling $2,089. Earlier in the week she received restricted stock units and option grants. The company also drew a Buy initiation from Clear Street with a $13.00 price target, while InvestingPro flags volatility and …
Ruhi Ahmad Khan, Chief Business Officer at Caribou Biosciences (CRBU), sold 6,938 shares on February 24, 2026, for $1.96 apiece to satisfy tax obligations tied to restricted stock unit vesting. The filings show earlier acquisitions on February 20, 2026 — 45,000 shares at a reported value of $0 and options to buy 202,500 shares at $1.80 that vest mo…
Ameris Bancorp Chief Financial Officer Nicole S Stokes reported a nominal sale of company stock on February 24, 2026, alongside other equity movements tied to compensation and tax-withholding. The $5.4 billion regional bank also released fourth-quarter 2025 results that slightly beat EPS expectations but missed revenue estimates. Separately, the co…
Benjamin C. Singer, Procore Technologies’ Chief Legal Officer and Secretary, sold 6,938 shares of the company’s common stock between February 23 and February 24, 2026, for roughly $348,023 under a pre-existing 10b5-1 trading arrangement. The stock trades near its 52-week low and had seen a roughly 23% decline over six months. Procore also reported …
Palantir Technologies Chief Accounting Officer Jeffrey Buckley sold 4,646 shares of Class A common stock on February 20 and February 24, 2026, in automated transactions executed under a Rule 10b5-1 plan to satisfy tax withholding tied to vesting restricted stock units. The trades realized roughly $520,000 in proceeds. Palantir shares are trading ma…
Palantir Technologies Inc's CFO and Treasurer, David A. Glazer, disposed of 17,488 shares of Class A common stock on February 20, 2026, in a series of automated transactions to satisfy tax-withholding obligations tied to restricted stock unit vesting. The sales, carried out under a Rule 10b5-1 plan, totaled $2,331,782 based on prices between $132.0…
Palantir Technologies' Chief Technology Officer and Executive Vice President, Sankar Shyam, sold $22.5 million of Class A Common Stock on February 20, 2026, in several transactions. The same day he converted a large block of Class B shares to Class A and received restricted stock units upon vesting. The stock has been under pressure year-to-date, w…
Ryan D. Taylor, an officer at Palantir Technologies Inc (NYSE: PLTR), sold 20,338 Class A shares on February 20, 2026, receiving $2.67 million in proceeds. The disposition was filed on a Form 4 with the SEC and occurred while the stock trades down 27.5% year-to-date and around $128.82 per share. The company has announced a partnership with Rackspac…
ImmunityBio director Christobel Selecky sold 25,000 shares on February 23, 2026, for $10 apiece, generating $250,000. On the same day she exercised options to buy 25,000 shares at $2.98, a transaction worth $74,500. The sale was carried out under a Rule 10b5-1 plan. The company has reported substantial revenue growth for its cancer therapy ANKTIVA,…
Palantir Technologies CEO Alexander C. Karp sold $65.9 million worth of Class A common stock in a series of transactions on February 20, 2026, and completed several conversions of Class B shares to Class A. The stock is trading below the sales range and is viewed by one service as overvalued versus Fair Value, even as analysts upgraded the shares a…
Palantir Technologies director Stephen Andrew Cohen sold $43.7 million of Class A Common Stock on February 20, 2026 across a series of transactions. The company’s shares have fallen 27.5% year-to-date and trade at a high price-to-earnings multiple. Cohen also converted Class B shares to Class A and restricted stock units were exercised into Class B…
Barry J. Simon, a director at ImmunityBio, sold 175,000 shares of the company’s common stock in late February 2026 for roughly $1.78 million under a pre-arranged Rule 10b5-1 plan. The transactions occurred as the stock traded above its 52-week high amid substantial revenue growth for the company’s cancer therapy ANKTIVA and new distribution deals i…
KalVista Pharmaceuticals CFO Brian Piekos sold 1,767 shares on February 23, 2026, netting $27,506 at a weighted average price of $15.5668 per share. Earlier in the week he exercised options on 5,000 shares and converted 5,000 restricted stock units into common stock. The insider moves come as KalVista reports preliminary fourth-quarter 2025 revenue…
KalVista Pharmaceuticals Chief Medical Officer Paul K. Audhya sold 5,354 shares on February 23, 2026, generating about $83,344. The sale followed the exercise and conversion of 11,250 restricted stock units into common shares on February 21 and 22. KalVista's stock trades around $15.77, and the company reported preliminary global EKTERLY sales of r…
Nicole Sweeny, chief commercial officer of KalVista Pharmaceuticals (KALV), sold 3,975 shares of common stock on February 23, 2026, to satisfy tax-withholding tied to vested RSUs. The sale totaled about $61,878 at a weighted average price of $15.5668. The company reported preliminary fourth-quarter 2025 EKTERLY revenue of roughly $35 million, well …
Christopher Yea, Chief Development Officer at KalVista Pharmaceuticals (KALV), sold 4,347 shares on February 23, 2026, to satisfy tax-withholding obligations stemming from the vesting and settlement of restricted stock units. The transaction was non-discretionary, according to a Form 4 filing. Separately, KalVista reported roughly $35 million in gl…
KalVista Pharmaceuticals Chief Executive Officer Benjamin L. Palleiko sold 10,034 shares on February 23, 2026 to cover tax withholding obligations, realizing roughly $156,197. The company reported about $35 million in fourth-quarter 2025 revenue from its oral HAE treatment EKTERLY, contributing to approximately $49 million in full-year sales after …
